What is ADC Therapeutics's market cap?

ADC Therapeutics (ADCT) has a market capitalization of $145.0M and trades on NYSE.

Who are ADC Therapeutics's competitors?

ADC Therapeutics's key competitors include Gilead Sciences, Seagen, ImmunoGen, and others. These companies compete in similar markets and product categories.

Who does ADC Therapeutics partner with?

ADC Therapeutics's notable partners include Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals.

What subsidiaries does ADC Therapeutics have?

ADC Therapeutics's subsidiaries include ADC Therapeutics America, Inc..

Where is ADC Therapeutics headquartered?

ADC Therapeutics is headquartered in Switzerland and employs approximately 274 people. It has been publicly traded since 2020.

ADC Therapeutics

ADCT

Market cap

$145M-56.1%

Table of contents

Earnings

Q1 2026 report

May 4, 2026

Revenue$20.9MBeat by $864.2K EPS-$0.21Miss by $0.02

Read the full report

Next report

Aug 11, 2026 (In 1 week)

Revenue estimate$18.9M

EPS estimate-$0.19

Competitors

By market cap

AbbVie$453.91B+36.3%

Gilead Sciences$162.05B+15.3%

Pfizer$140.61B+1.7%

Pyxis Oncology$184.4M+143%

Corbus Pharmaceuticals$168.2M+43.4%

ADC Therapeutics$145.0M-58.6%

CTO

Citius Oncology, Inc.$51.7M-64.7%

BioAtla, Inc.$5.6M-72.7%

By revenue growth

AbbVie+9.5%

Gilead Sciences+3.5%

Pfizer+1.4%

By net margin

Gilead Sciences30.99%+10.2pp

Pfizer15.65%+6.3pp

AbbVie5.79%-1.5pp

Profile

ADC Therapeutics is a commercial-stage biotechnology company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company leverages specialized capabilities in clinical development and manufacturing to deliver targeted therapies that combine the specificity of antibodies with the potency of cytotoxic agents. Its primary value proposition centers on its proprietary ADC platform, led by its first FDA-approved product for relapsed or refractory diffuse large B-cell lymphoma.

Competitive position

A commercial-stage pioneer in the ADC space with an established regulatory footprint in major global markets and a deep pipeline of next-generation conjugates.

GeographiesUnited States, European Union, China, Switzerland, Canada

Customer segmentsHealthcare providers, Wholesale distributors, Biopharmaceutical companies

Business modelR&D intensive, Direct product sales, Licensing and royalties

SuppliersContract manufacturing organizations, Specialized chemical suppliers, Clinical trial sites, Antibody discovery platforms

CustomersSpecialty distributors, Group purchasing organizations, Cancer treatment centers, Regional pharmaceutical licensees

CountrySwitzerland

Listed2020

Employees274.0

CEOAmeet Mallik

SectorHealthcare

IndustryBiotechnology

Websiteadctherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is ADC Therapeutics's market cap?: ADC Therapeutics (ADCT) has a market capitalization of $145.0M and trades on NYSE.
Who are ADC Therapeutics's competitors?: ADC Therapeutics's key competitors include Gilead Sciences, Seagen, ImmunoGen, and others. These companies compete in similar markets and product categories.
Who does ADC Therapeutics partner with?: ADC Therapeutics's notable partners include Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals.
What subsidiaries does ADC Therapeutics have?: ADC Therapeutics's subsidiaries include ADC Therapeutics America, Inc..
Where is ADC Therapeutics headquartered?: ADC Therapeutics is headquartered in Switzerland and employs approximately 274 people. It has been publicly traded since 2020.